Get the app
US › Healthcare

Zura Bio Limited Class A Ordinary Shares (ZURA)

US · Healthcare · Biotechnology

$4.57-0.87%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-26.3M
EPS
$-0.21
EPS estimate
$-0.20

EPS came in at -0.21 against a street estimate of -0.20 — a miss of 5.0%.

Key statistics

Market cap
$515.6M
Forward P/E
0.0
P/B
2.78
Book value
$2.06
EPS (TTM)
$-1.12
52-week high
$7.44
52-week low
$1.88
50-day MA
$5.59
200-day MA
$5.26
Beta
-0.03

Analyst view

Analysts rate Zura Bio Limited Class A Ordinary Shares a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $18.00.

Shareholding

Insiders
18.92%
Institutions
87.84%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.46%
VR Adviser, LLC6.72%
MPM Oncology Impact Management LP4.67%
JPMorgan Chase & Co4.65%
Great Point Partners LLC4.40%
BRAIDWELL LP4.16%
Siren, L.L.C.3.90%
COMMODORE CAPITAL LP3.39%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zura Bio Limited Class A Ordinary Shares — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.